Francis Richard D 4

What Happened

• Richard D. Francis, President and CEO of Teva Pharmaceuticals (TEVA), was granted two awards totaling 1,511,425 restricted share units (RSUs) on January 27, 2026: 620,110 RSUs and 891,315 RSUs. Each RSU was granted with a $0.00 acquisition price (award/derivative), meaning these are contingent awards rather than purchases. These RSUs represent rights to receive one ordinary share (or, at the committee’s option, the cash value) upon settlement.

Key Details

• Transaction date: January 27, 2026; Form 4 filed January 29, 2026 (not indicated as late).
• Grant details: 620,110 RSUs and 891,315 RSUs; grant price $0.00 (transaction code A — award/grant).
• Vesting: per footnotes, portions of the award vest on February 15, 2026 (620,110 RSUs) and March 3, 2026 (891,315 RSUs).
• Derivative note: RSUs are contingent rights to ordinary shares or cash (Human Resources & Compensation Committee may elect cash).
• ADS note: Ordinary shares may be represented by American Depositary Shares (each currently representing one Ordinary Share).
• Shares owned after transaction: not specified in this filing.

Context

• These awards originated from performance share units that satisfied performance criteria and remain subject to time‑based vesting — this is an award conversion rather than an open‑market purchase or sale. Awards and RSU grants are common executive compensation and do not by themselves indicate a buy/sell signal; they simply reflect equity compensation and vesting schedules.